<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984113</url>
  </required_header>
  <id_info>
    <org_study_id>07-115 / CPRT128A2104</org_study_id>
    <nct_id>NCT00984113</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment</brief_title>
  <official_title>An Open-label, Parallel-group Study to Determine the Single and Multiple Dose Pharmacokinetics of Elinogrel and Its Metabolite in Patients With Mild, Moderate, and Severe Renal Impairment Compared to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the pharmacokinetics and safety of elinogrel and its
      metabolite in patients with mild, moderate, and severe renal impairment compared to healthy
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple-dose, open-label parallel-group design in patients with mild, moderate or severe
      renal impairment and age (±7 years), sex and weight (±15% BMI) matched healthy subjects.

        -  mild renal impairment: CrCl from 50 to ≤80 ml/min

        -  moderate renal impairment: CrCl from 30 to &lt;50 ml/min

        -  severe renal impairment: CrCl of &lt;30 ml/min
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    For administrative reasons. Enrollment was sufficient to have statistical power without
    compromising the integrity of the study data
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of elinogrel and its metabolite</measure>
    <time_frame>7 days</time_frame>
    <description>The PK parameters calculated for both elinogrel and PRT060301 were:
AUC0-12h, Cmax, and Tmax on Day 1/Day 7 and T1/2, RACC &amp; CLR on Day 7
For elinogrel only, CLss/F and Vss/F were also calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments will include vital signs, electrocardiograms and adverse events</measure>
    <time_frame>9 days</time_frame>
    <description>Safety assessments consisted of collecting all adverse events (AEs), serious adverse events (SAEs), with their severity and relationship to study drug, and pregnancies, regular monitoring of hematology, blood chemistry and urinalysis performed at study center. Safety assessments also included periodic ECG evaluations, assessments of vital signs, physical condition, and body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of platelet function</measure>
    <time_frame>7 days</time_frame>
    <description>Platelet aggregation using VerifyNOW P2Y12 assay and thrombi formation using Portola's proprietary PCA (Perfusion Chamber Assay).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>A-Patients with mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B-Healthy subjects matched to Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C-Patients with moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D-Healthy subjects matched to Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E-Patients with severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F-Healthy subjects matched to Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elinogrel</intervention_name>
    <description>100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)</description>
    <arm_group_label>A-Patients with mild renal impairment</arm_group_label>
    <arm_group_label>B-Healthy subjects matched to Group A</arm_group_label>
    <arm_group_label>C-Patients with moderate renal impairment</arm_group_label>
    <arm_group_label>D-Healthy subjects matched to Group C</arm_group_label>
    <arm_group_label>E-Patients with severe renal impairment</arm_group_label>
    <arm_group_label>F-Healthy subjects matched to Group E</arm_group_label>
    <other_name>PRT060128</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand and sign the written informed consent

          -  Subjects should have either normal renal function or have stable renal disease

        Exclusion Criteria:

          -  History of heart disease

          -  Unstable or clinically significant other disorders such as respiratory, hepatic,
             metabolic, psychiatric or gastrointestinal disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew W McClure, MD</last_name>
    <role>Study Director</role>
    <affiliation>Portola Pharmaceuticals Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOCR-Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>November 22, 2010</last_update_submitted>
  <last_update_submitted_qc>November 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Matthew W. McClure, MD</name_title>
    <organization>Portola Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Elinogrel</keyword>
  <keyword>Renal impairment</keyword>
  <keyword>Healthy</keyword>
  <keyword>Kidney dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

